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etter to the Editorharacterization  of  the  high-risk  human  papillomavirus
nfection in Jining,  China
had  triple infections. While no cases were  infected by fourear Editor,
uman papillomaviruses (HPV) is from the genus Alphapapil-
omavirus, family Papillomaviridae. Of the over 120 HPV types
hat  have been identiﬁed, about a dozen types are called “high-
isk”  types (HR-HPV) because they can lead to cervical cancers.
herefore,  early diagnosis of HPV infection and character-
ze  the HPV types becomes a key issue for cervical cancer
revention.1,2 Our study characterized the HR-HPV infections
nd  genotypes in Jining, a medium sized city located in the
ast  part of China, with a RT-PCR and hybridization method.
The  study population consisted of 6234 women  who
ttended the Afﬁliated Hospital of Jining Medical College for
ervical  smears between January 2010 and May 2012. The
verage  age of the participants was  37 years old (range:
4–79  years). Overall 13.47% (840/6234) of the tested women
ere  found to be positive for HR-HPV infection. Out of the
40  women  infected with HR-HPV, 701 women (11.24%) were
nfected  with a single HR-HPV genotype and the remaining 139
omen (2.23%) were  infected with multiple genotypes. Anal-
sis  of the relationship between age and HR-HPV genotype
howed that younger woman had a higher rate of infec-
ion.  In the study populations of woman aged over 50 and
ged  between 40 and 49 years old, the HR-HPV infection
Table 1 – The prevalence of HR-HPV.a
Total
(n = 6234)
≥50
(n = 526)
40–49
(n  = 1918)
HR-HPV negative 5394 (86.53%) 458 (87.07%) 1700 (88.63%) 
HR-HPV positive 840 (13.47%) 68 (12.93%) 218 (11.37%) 
Single infection 701 (11.24%) 57 (10.84%) 182 (9.49%) 
Multiple infection 139 (2.23%) 11 (2.09%) 36 (1.88%) 
a HR-HPV types: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68.
b The 296 samples with no information on birth dates were excluded.
∗ Signiﬁcant if p < 0.05, Chi-square test.rate were 12.93% and 11.37%, respectively. The rates rose to
15.93%  and 16.67% for woman aged 26–29 years old and for
teenage  women, respectively (p < 0.05). When single infection
and  multiple infection were analyzed separately, although
there  was no multiple infection cases were  found among
teenage women, which might be due to the small study sample
from  this group, both single infection and multiple infection
showed  the same trend.
When the HR-HPV genotypes were considered separately,
HR-HPV 16 was  the most prevalent type (361/6234 = 5.79%), and
HR-HPV  58 (2.58%) and 52 (2.50%) ranked the second and the
third,  respectively, followed by 33, 31, 18 and 39. The preva-
lence  of each HR-HPV type in each age group was  determined
too  (Table 1). In all of the ﬁve study groups, HR-HPV 16 ranked
ﬁrst.  While HR-HPV 52 ranked second in populations aged over
50  and aged between 30 and 39 years old, HR-HPV 58 ranked
second  in the remaining age strata, and HR-HPV 52 ranked
third.
Among  the 132 multiple infection cases, 122 women  were
infected  by dual infections (122/6234 = 1.96%) and 15 womenAge  groupsb
30–39
(n  = 2309)
20–29
n  = 1463)
<20
n = 18)
p-value*
1991 (86.23%) 1230 (84.07%) 15 (83.33%) N.A.
318 (13.77%) 233 (15.93%) 3 (16.67%) 0.04
264 (11.43%) 195 (13.33%) 3 (16.67%) 0.01
54 (2.34%) 38 (2.60%) 0 0.63
HR-HPV  genotypes, 2 women, in the age-groups of 30–39 and
20–29,  respectively, were infected by ﬁve HR-HPV genotypes.
The  rates of infection with multiple HR-HPV were  higher in the
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younger age groups than in the older groups. In the 20–29 year
age  group, 2.6% (38/6234) were found to be infected with more
one  type of HR-HPV. The rated decreased to 1.88% (36/1918)
and  2.09% (11/526) in the 40–49 age group and over 50 age
group,  respectively. In the multiple HR-HPV infected popula-
tion,  HR-HPV 16, 52 and 58 ranked as the ﬁrst three most com-
mon  genotypes with minor variation in different age groups.
Previous  studies showed that infection with high-risk HPV
is  the predominant cause of cervical cancers.1,2 The launch-
ing  of HPV vaccines greatly beneﬁts the women  by reducing
the  HPV infection rate. The two available vaccines, which are
the  quadrivalent vaccine and the bivalent vaccine, differ in
that  the quadrivalent vaccine contains VLPs from recombi-
nant  HPV 6, 11, 16 and 18, and aims at preventing cervical
cancer intraepithelial neoplasia (CIN2, 3), cervical cancer and
genital  warts, while the latter only contains recombinant VLPs
against  HPV 16 and 18 and, therefore cannot confer protection
against  genital warts.3,4 Since the geographical distribution
of  HPV types coevolved with human population migration
and  behavioral changes, early diagnosis and characterization
the HPV types is an important step toward the development
of  optimal protective strategies. The result of this study will
provide  important information for the application of future
prophylactic vaccine program.5
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